MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: A meta-analysis

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4147-4151

  Chen, Qi Wen ^a,b   Chen, Hao ^a,b   Cheng, Jian Shan ^c   Meng, Zhi Qiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; MDM2; Meta analysis; Polymorphism

Indexed keywords

PROTEIN MDM2; MDM2 PROTEIN, HUMAN;

ARTICLE; ASIAN; CANCER RISK; CAUCASIAN; CHINESE; ETHNICITY; GENE; GENE FREQUENCY; GENE MDM2; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PUBLISHING; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; META ANALYSIS; RISK;

CARCINOMA, HEPATOCELLULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; PUBLICATION BIAS; RISK;

EID: 84902952070     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1543-z     Document Type: Article

References (22)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer:worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-16.
2. Picksley SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays. 1993;15(10):689-90.
3. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol. 1993;13(7):4107-14. (Pubitemid 23187639)
4. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296-9. (Pubitemid 27220766)
5. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver. 2000;20(3):209-15. (Pubitemid 30342718)
6. Schöniger-Hekele M, Hänel S, Wrba F, Müller C. Hepatocellular carcinoma - survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int. 2005;25(1):62-9. (Pubitemid 40298246)
7. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602. (Pubitemid 39535748)
8. Qin X, Peng Q, Tang W, Lao X, Chen Z, Lai H, et al. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk. PLoS One. 2013;8(9):e76031.
9. Ma Y, Bian J, Cao H.MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One. 2013;8(2):e56918.
10. Zhuo W, Zhang L, Zhu B, Ling J, Chen Z. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One. 2012;7(7):e41546.
11. Liu G, Jiang D, Shen S, Yu L. Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis. Int J Urol. 2012;19(10):914-20.
12. Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma. 2012;53(11):2245-52.
13. Akkiz H, Sümbül AT, Bayram S, Bekar A, Akgöllü E. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol. 2010;34(4):448-52.
14. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12(16):4867-71. (Pubitemid 44338572)
15. Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6:13.
16. Ezzikouri S, El Feydi AE, Afifi R, El Kihal L, Benazzouz M, Hassar M, et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev. 2009;32(5-6):380-5.
17. Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol. 2009;15(44):5592-7.
18. Wang X, Zhang X, Qiu B, Tang Y, Sun H, Ji H, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32(7):1172-8.
19. Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4(1):71-81.
20. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29(6):1192-6. (Pubitemid 351964880)
21. Liu GY, Jiang DK, Shen SQ, Yu L. MDM2 SNP309T>G polymorphismwith hepatocellular carcinoma risk: a meta-analysis. Arch Med Res. 2011;42(2):149-55.
22. Ma HB, Huang T, Han F, Chen WY. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a metaanalysis. Asian Pac J Cancer Prev. 2012;13(6):2841-6.